Regeneron Pharmaceuticals, Inc.’s two-antibody cocktail for coronavirus infection, REGN-COV2 (casirivimab/imdevimab), will join Eli Lilly and Company’s antibody product, helping to ease the immediate demand for a COVID-19 treatment, but the long-term potential of these antibody treatments remains uncertain as the introduction of vaccines are expected to taper off infections.
On 21 November, Regeneron received an emergency use authorization for casirivimab and imdevimab (previously known as REGN-COV2 or REGEN-COV2) from...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
